FDA rejects Coherus’s biosimilar for Neulasta, shares plunge

Short resume:

coherus
80%
data
60%
amgen
50%
stock
40%

Coherus BioSciences Inc said on Monday the U.S. Food and Drug Administration (FDA)30 declined to approve its biosimilar copy of Amgen Inc’s blockbuster treatment, Neulasta, which is used to fight infections in cancer patients.
Source Reuters
Read More…

More News


Be the first to comment

Leave a Reply

Your email address will not be published.


*